Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Deep Bio’s AI-Based Antibody Optimization Platform Applied to Parkinson’s Disease

  • Collaborative research between Deep Bio and AngioLab for the development of a new mAb for PD

Deep Bio, a leading AI biotech dedicated to pathologic cancer diagnosis and prognosis, announced an on-going joint research with AngioLab, a Korean biotech with a long track record in angiogenesis, on a new monoclonal antibody for Parkinson’s disease.

The R&D collaboration aims to find the most optimized antibody by applying Deep Bio’s AI technology to promising candidates. For the research, Deep Bio is developing and will be applying an AI-based algorithm to identify antibodies with the highest affinity to the target.

Recommended AI News: Brave Bison Acquiring Leading Digital Performance & Commerce Agency Greenlight

The antibody candidates that AngioLab has discovered target a completely different protein from that of Alpha-synuclein (α-Syn) which has led to disappointing results in clinical trials. The antibody under study, if successful, has the potential to become an effective treatment option for patients with Parkinson’s disease.

“We are pleased to participate in a drug R&D for Parkinson’s disease where new treatment options are in need. Utilizing our AI-based algorithm will dramatically reduce the time and cost for drug optimization,” said the CEO of Deep Bio. “At the same time, we will use this opportunity to expand our business to AI drug discovery and development, in addition to digital pathology, and contribute to the advancement of the healthcare industry.”

Recommended AI News: Enterprises In Germany Turn To Cybersecurity Providers To Help With Pandemic Challenges

Min-Young Kim, the CEO of AngioLab, said, “applying Deep Bio’s state-of-the-art AI technology to optimize antibodies allows us to be more efficient in this critical step of the drug development process. This partnership will contribute to expanding our antibody drug pipeline.”

Deep Bio develops and implements deep learning-based software that can help medical professionals optimize their decisions and determine the best treatment options for patients. Dedicated to developing innovative solutions in the digital healthcare sector, the company is in multiple collaborations with renowned universities and laboratories around the world.

Recommended AI News: Phunware Launches Smart City Solution for the City of Pasadena

Comments are closed.